Rapid reporting and review of an increased incidence of a known adverse event

Journal of the National Cancer Institute

Volumn 92, Issue 12, 2000, Pages 1011-1013

  Sargent, Daniel J ^a   Goldberg, Richard M ^a   Mahoney, Michelle R ^a   Hillman, David W ^a   McKeough, Timothy ^a   Hamilton, Sonja F ^a   Darcy, Jennifer M ^a   Anderson, Victoria L ^a   Krook, James E ^a   O'Connell, Michael J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT;

ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER PROGRAM; DIARRHEA; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; UNITED STATES; VOMITING;

EID: 17044455393     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.12.1011     Document Type: Article

References (4)

1. http://www.fda.gov/medwatch/report/desk/advevnt.htm.
2. http://ctep.info.nih.gov/ctc3/ctc-manual.htm.
3. Christian M, Shoemaker D. Investigators handbook: a manual for participation in clinical trials of investigational agents sponsored by DCTD, National Cancer Institute; 1998; http://ctep.info.nih.gov/handbook/handbook/default.htm.
4. Title 21. Code of federal regulations. Part 312.